Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

Last updated: July 30, 2020
Sponsor: Jonsson Comprehensive Cancer Center
Overall Status: Completed

Phase

3

Condition

Multiple Myeloma

Cervical Cancer

Lymphoma

Treatment

N/A

Clinical Study ID

NCT00006083
CDR0000068075
NCI-G00-1822
P-UPJOHN-98-FRAG-076
UCLA-9910055
  • Ages > 18
  • All Genders

Study Summary

RATIONALE: The use of dalteparin may be able to prevent complications caused by the use of a catheter to supply chemotherapy to cancer patients. It is not yet known if dalteparin is effective in reducing these complications.

PURPOSE: Randomized phase III trial to determine the effectiveness of dalteparin in preventing catheter-related complications in cancer patients who are receiving chemotherapy through a catheter.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically confirmed malignancy

  • No more than 5 days since placement of central venous catheter for administration ofchemotherapy

  • Expected length of catheter use at least 16 weeks

  • 18 and over

  • Performance status: ECOG 0-2

  • Life expectancy: At least 16 weeks

  • Hematopoietic:

  • Platelet count at least 100,000/mm3

  • Absolute neutrophil count at least 1,500/mm3

  • No known coagulopathy

  • Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) except in caseof Gilbert's syndrome

  • AST no greater than 3 times ULN (no greater than 5 times ULN in case of livermetastases)

  • PT/PTT no greater than 1.5 times ULN Renal:

  • Creatinine no greater than 2 times ULN Cardiovascular:

  • HIV negative

  • Must weigh at least 90 pounds

  • At least 3 months since prior eye, ear, or CNS surgery Other:

  • At least 30 days since prior aspirin, dipyridamole, unfractionated heparin, other lowmolecular weight heparins, or other anticoagulation therapy (except heparin flushing)

Exclusion

Exclusion Criteria:

  • uncontrolled hypertension, unstable angina, or symptomatic congestive heart failure

  • myocardial infarction in past 6 months

  • uncontrolled cardiac arrhythmia Other:

  • known hypersensitivity (including heparin induced thrombocytopenia) to dalteparin,heparin, or other low molecular weight heparins

  • active uncontrolled infection, including existing catheter related infection

  • CNS trauma in past 3 months

  • retinal detachment in past 6 months

  • mental incapacitation or psychiatric illness that would preclude study compliance

  • other serious concurrent disease that would preclude study participation

  • active gastrointestinal or genitourinary tract bleeding

  • intracranial or intraocular hemorrhage in past year

  • concurrent high dose chemotherapy with stem cell transplantation

  • concurrent induction/consolidation chemotherapy for leukemia

  • concurrent high dose chemotherapy with stem cell transplantation

Study Design

Study Start date:
April 01, 2000
Estimated Completion Date:
November 30, 2000

Study Description

OBJECTIVES: I. Determine if dalteparin will reduce the incidence of clinically significant catheter related complications (i.e., asymptomatic catheter related thrombosis) in cancer patients receiving chemotherapy through a central venous catheter.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to treatment center and catheter placement (proximal to axilla vs distal to axilla). Patients are randomized to one of two treatment arms. Arm I: Patients receive dalteparin subcutaneously (SC) daily. Arm II: Patients receive placebo SC daily. Treatment continues for 16 weeks or until catheter removal in the absence of unacceptable toxicity. Patients are followed for 30 days.

PROJECTED ACCRUAL: A total of 345 patients (230 in arm I and 115 in arm II) will be accrued for this study over 6 months.

Connect with a study center

  • Jonsson Comprehensive Cancer Center, UCLA

    Los Angeles, California 90095-1781
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.